Výsledky vyhledávání - "Nishit B. Modi"

Akademický článek

JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans

Publikováno v: Scientific Reports, Vol 14, Iss 1, Pp 1-12 (2024)

Abstract The interleukin (IL)-23 pathway is a pathogenic driver in psoriasis, psoriatic arthritis, and inflammatory bowel disease. Currently, no oral therapeutics selectively target this pathway. JNJ-77242113 is a peptide targeting the IL-23 receptor

Externí odkaz: https://doaj.org/article/a5c225b49e4844578be75fc534d1282c

Zobrazit plný text záznamu

Single‐ and Multiple‐Dose Pharmacokinetics and Pharmacodynamics of PN‐943, a Gastrointestinal‐Restricted Oral Peptide Antagonist of α4β7, in Healthy Volunteers

Autor: Larry C. Mattheakis, Suneel K. Gupta, Ching‐Chang Hwang, Xiaoli Cheng, David Liu, Nishit B. Modi, Roya Nawabi

Publikováno v: Clinical Pharmacology in Drug Development

PN‐943 is an orally stable, gastrointestinal‐restricted peptide that binds specifically to α4ß7 integrin on leukocytes, blocking leukocyte trafficking to and activation in the gut, inhibiting colon inflammation and reducing signs and symptoms o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2d804a0d7b4e7eec6fdab91fa3ce79e
https://doi.org/10.1002/cpdd.946

Zobrazit plný text záznamu

Plný text ve formátu HTML

Pharmacodynamics, Efficacy, and Safety of IPX203 in Parkinson Disease Patients With Motor Fluctuations

Autor: Phillip Dinh, Suneel K. Gupta, Nishit B. Modi, Robert Rubens, Aravind Mittur

Publikováno v: Clinical Neuropharmacology

Objectives IPX203 is an investigational oral extended-release capsule formulation of carbidopa and levodopa. The pharmacodynamics and efficacy of IPX203 were compared with immediate-release carbidopa-levodopa (IR CD-LD) in this open-label, rater-blin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3186e4d987dec7f9df6ea2ab8fff8850
https://doi.org/10.1097/wnf.0000000000000354

Zobrazit plný text záznamu

PTG-100, an Oral α4β7 Antagonist Peptide

Autor: Raj Bhandari, Rish K. Pai, Larry C. Mattheakis, David Pugatch, David Liu, Scott D. Lee, Nishit B. Modi, Brian Bressler, Bittoo Kanwar, Stefan Schreiber, Brian G. Feagan, Silvio Danese, Geert R. D'Haens, Richard Shames, William J. Sandborn, Suneel K. Gupta

Publikováno v: Gastroenterology, 161(6), 1853-1864.e10. W.B. Saunders Ltd

Background & Aims Oral therapies targeting the integrin α4β7 may offer unique advantages for the treatment of inflammatory bowel disease. We characterized the oral α4β7 antagonist peptide PTG-100 in preclinical models and established safety, phar

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f027461942f2d46565a584a390cf617
http://www.scopus.com/inward/record.url?scp=85117830253&partnerID=8YFLogxK

Zobrazit plný text záznamu

A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera

Autor: Frank Valone, Andrew T. Kuykendall, Naveen Pemmaraju, Sarita Khanna, Suneel K. Gupta, Srdan Verstovsek, Jean-Jacques Kiladjian, Yelena Ginzburg, Nishit B. Modi, Paula G. O'Connor, Ronald Hoffman

Publikováno v: Blood. 138:1504-1504

Background. Polycythemia vera (PV) patients are treated with periodic therapeutic phlebotomy (TP) alone or in combination with either hydroxyurea (HU), ruxolitinib (RUX) or interferon (IFN) to maintain hematocrit (HCT) levels below 45% as per NCCN gu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5b7cdb8ccfccc9ae265789935abfeddf
https://doi.org/10.1182/blood-2021-149219

Zobrazit plný text záznamu

Rusfertide (PTG-300), a Hepcidin Mimetic, Maintains Liver Iron Concentration in the Absence of Phlebotomies in Patients with Hereditary Hemochromatosis

Autor: Christopher Ferris, Suneel K. Gupta, Frank Valone, Frank Cole, Nishit B. Modi, Victor M. Priego, Kris V. Kowdley

Publikováno v: Blood. 138:943-943

Introduction: Patients with hereditary hemochromatosis (HH) require continued phlebotomies to limit end-organ damage. Approximately 25% of patients in maintenance felt receiving phlebotomies was "inconvenient" or "very inconvenient" (Brisott et al, 2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c86800d4072749d769040cd9a3cbd0d0
https://doi.org/10.1182/blood-2021-149197

Zobrazit plný text záznamu

Rusfertide (PTG-300) Induction Therapy Rapidly Achieves Hematocrit Control in Polycythemia Vera Patients without the Need for Therapeutic Phlebotomy

Autor: Sung-Eun Lee, Suneel K. Gupta, Veena Selvaratnam, Kamini Kirubamoorthy, Yelena Ginzburg, Ronald Hoffman, Sarita Khanna, Nishit B. Modi, Frank Valone, Lee Ping Chew, Jae Hoon Lee, Sinari Salleh

Publikováno v: Blood. 138:390-390

Background. Polycythemia (PV) patients with hematocrit above 45% are at increased risk of thrombotic complications and are treated with phlebotomy and/or cytoreductive therapy to reach a hematocrit target below 45%. Rusfertide (PTG-300) is a peptidic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d07d3497dbc4492f2344beb59ee7f581
https://doi.org/10.1182/blood-2021-149205

Zobrazit plný text záznamu

Pharmacokinetics of Rytary®, An Extended-Release Capsule Formulation of Carbidopa–Levodopa

Autor: Nishit B. Modi, Aravind Mittur, Suneel K. Gupta

Publikováno v: Clinical Pharmacokinetics. 56:999-1014

Parkinson’s disease (PD) is a chronic progressive neurological disorder characterized by resting tremor, rigidity, bradykinesia, gait disturbance, and postural instability. Levodopa, the precursor to dopamine, coadministered with carbidopa or bense

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a8f1d21bd70024825281162a1b59ffc
https://doi.org/10.1007/s40262-017-0511-y

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání